P. aeruginosa Antimicrobial Resistance
The proportion of
P. aeruginosa resistant to carbapenems, quinolones, and third-generation cephalosporins has steadily increased in the last two decades, including multidrug-resistant (MDR) infections (resistance to at least three of four drug classes: carbapenems, ceftazidime, ciprofloxacin and tobramycin). The resistance mechanisms of
P. aeruginosa include the production of beta-lactamases, efflux pumps, and target-site or outer membrane modifications; heavily encapsulated (mucoid) strains and those establishing dense biofilms pose additional problems for eradication.